Periprocedural anticoagulation during left atrial ablation: interrupted and uninterrupted vitamin K-antagonists or uninterrupted novel anticoagulants.

ABSTRACT:

Background

There is a lack of data on anticoagulation requirements during ablation of atrial fibrillation (AF). This study compares different oral anticoagulation (OAC) strategies to evaluate risk of bleeding and thromboembolic complications.

Methods

We conducted a single-centre study in patients undergoing left atrial ablation of AF. Three groups were defined: 1) bridging: interrupted vitamin-K-antagonists (VKA), INR ≤2, and bridging with heparin; 2) VKA: uninterrupted VKA and INR of > 2; 3) DOAC: uninterrupted direct oral anticoagulants. Bleeding complications, thromboembolic events and peri-procedural heparin doses were assessed.

Results

In total, 780 patients were documented. At 48 h, major complications were more common in the bridging group compared to uninterru

SUBMITTER: Brinkmeier-Theofanopoulou M 

PROVIDER: S-EPMC5924498 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature